Trial Profile
An Open Label, Pharmacogenetic Study of Bisoprolol Treatment in Patients With Uncontrolled Essential Hypertension (BRAVE)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bisoprolol (Primary)
- Indications Essential hypertension
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms BRAVE
- 04 Jan 2021 Status changed from recruiting to completed.
- 31 Mar 2015 New trial record